The University of Chicago Header Logo

Connection

David A. Ehrmann to Polycystic Ovary Syndrome

Back to Details
This is a "connection" page, showing publications David A. Ehrmann has written about Polycystic Ovary Syndrome.
David A. Ehrmann
Connection Strength
10.081
Polycystic Ovary Syndrome
  1. Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome. Fertil Steril. 2022 05; 117(5):897-911.
    View in: PubMed
    Score: 0.674
  2. Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome. Diabetologia. 2017 09; 60(9):1656-1661.
    View in: PubMed
    Score: 0.485
  3. Obstructive sleep apnea and polycystic ovary syndrome: cause or association? Sleep Med. 2017 08; 36:170-171.
    View in: PubMed
    Score: 0.467
  4. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016 10; 37(5):467-520.
    View in: PubMed
    Score: 0.452
  5. Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril. 2012 Jul; 98(1):242-9.
    View in: PubMed
    Score: 0.336
  6. Metabolic dysfunction in pcos: Relationship to obstructive sleep apnea. Steroids. 2012 Mar 10; 77(4):290-4.
    View in: PubMed
    Score: 0.328
  7. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod. 2011 Nov; 26(11):3138-46.
    View in: PubMed
    Score: 0.322
  8. Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2011 Feb; 96(2):365-74.
    View in: PubMed
    Score: 0.305
  9. Obstructive sleep apnea and metabolic dysfunction in polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab. 2010 Oct; 24(5):717-30.
    View in: PubMed
    Score: 0.302
  10. Variation in the perilipin gene (PLIN) affects glucose and lipid metabolism in non-Hispanic white women with and without polycystic ovary syndrome. Diabetes Res Clin Pract. 2009 Dec; 86(3):186-92.
    View in: PubMed
    Score: 0.281
  11. Impact of obstructive sleep apnea on insulin resistance and glucose tolerance in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008 Oct; 93(10):3878-84.
    View in: PubMed
    Score: 0.259
  12. Cardiometabolic features of polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab. 2008 Apr; 4(4):215-22.
    View in: PubMed
    Score: 0.251
  13. Pharmacologic therapy of polycystic ovary syndrome. Clin Obstet Gynecol. 2007 Mar; 50(1):244-54.
    View in: PubMed
    Score: 0.235
  14. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan; 91(1):48-53.
    View in: PubMed
    Score: 0.214
  15. Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan; 91(1):36-42.
    View in: PubMed
    Score: 0.214
  16. Polycystic ovary syndrome. N Engl J Med. 2005 Mar 24; 352(12):1223-36.
    View in: PubMed
    Score: 0.206
  17. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 Jan; 90(1):66-71.
    View in: PubMed
    Score: 0.200
  18. Letter to the Editor From Rosenfield, et al: "Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome". J Clin Endocrinol Metab. 2024 Sep 16; 109(10):e1962-e1963.
    View in: PubMed
    Score: 0.199
  19. Genetic contributions to glucose intolerance in polycystic ovary syndrome. Reprod Biomed Online. 2004 Jul; 9(1):28-34.
    View in: PubMed
    Score: 0.196
  20. Association of the (AU)AT-rich element polymorphism in PPP1R3 with hormonal and metabolic features of polycystic ovary syndrome. J Clin Endocrinol Metab. 2004 Jun; 89(6):2973-6.
    View in: PubMed
    Score: 0.195
  21. Androgens and mood dysfunction in women: comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom Med. 2004 May-Jun; 66(3):356-62.
    View in: PubMed
    Score: 0.193
  22. Impaired beta-cell compensation to dexamethasone-induced hyperglycemia in women with polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 2004 Aug; 287(2):E241-6.
    View in: PubMed
    Score: 0.188
  23. Pharmacologic treatment of polycystic ovary syndrome. Semin Reprod Med. 2003 Aug; 21(3):277-83.
    View in: PubMed
    Score: 0.184
  24. Relationship of insulin receptor substrate-1 and -2 genotypes to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab. 2002 Sep; 87(9):4297-300.
    View in: PubMed
    Score: 0.172
  25. Relationship of calpain-10 genotype to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab. 2002 Apr; 87(4):1669-73.
    View in: PubMed
    Score: 0.167
  26. Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene. J Clin Endocrinol Metab. 2002 Feb; 87(2):772-5.
    View in: PubMed
    Score: 0.166
  27. Insulin resistance and polycystic ovary syndrome. Curr Diab Rep. 2002 Feb; 2(1):71-6.
    View in: PubMed
    Score: 0.166
  28. Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab. 2001 May; 86(5):2027-31.
    View in: PubMed
    Score: 0.157
  29. Glucose intolerance in the polycystic ovary syndrome: role of the pancreatic beta-cell. J Pediatr Endocrinol Metab. 2000; 13 Suppl 5:1299-301.
    View in: PubMed
    Score: 0.143
  30. Insulin-lowering therapeutic modalities for polycystic ovary syndrome. Endocrinol Metab Clin North Am. 1999 Jun; 28(2):423-38, viii.
    View in: PubMed
    Score: 0.138
  31. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999 Jan; 22(1):141-6.
    View in: PubMed
    Score: 0.134
  32. Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genet. 2018 12; 14(12):e1007813.
    View in: PubMed
    Score: 0.133
  33. Attenuation of hyperinsulinemia in polycystic ovary syndrome: what are the options? J Endocrinol Invest. 1998 Oct; 21(9):632-5.
    View in: PubMed
    Score: 0.131
  34. Androgens, Irregular Menses, and Risk of Diabetes and Coronary Artery Calcification in the Diabetes Prevention Program. J Clin Endocrinol Metab. 2018 02 01; 103(2):486-496.
    View in: PubMed
    Score: 0.125
  35. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Jul; 82(7):2108-16.
    View in: PubMed
    Score: 0.120
  36. Relation of functional ovarian hyperandrogenism to non-insulin dependent diabetes mellitus. Baillieres Clin Obstet Gynaecol. 1997 Jun; 11(2):335-47.
    View in: PubMed
    Score: 0.120
  37. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Feb; 82(2):524-30.
    View in: PubMed
    Score: 0.117
  38. Hormonal Evaluation of Hyperandrogenism in Women. JAMA. 2015 Dec 15; 314(23):2557-8.
    View in: PubMed
    Score: 0.108
  39. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nat Commun. 2015 Aug 18; 6:7502.
    View in: PubMed
    Score: 0.106
  40. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest. 1995 Jul; 96(1):520-7.
    View in: PubMed
    Score: 0.105
  41. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev. 1995 Jun; 16(3):322-53.
    View in: PubMed
    Score: 0.104
  42. Adolescent polycystic ovary syndrome due to functional ovarian hyperandrogenism persists into adulthood. J Clin Endocrinol Metab. 2015 Apr; 100(4):1537-43.
    View in: PubMed
    Score: 0.102
  43. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 Dec; 98(12):4565-92.
    View in: PubMed
    Score: 0.093
  44. Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2013 Dec; 98(12):4646-54.
    View in: PubMed
    Score: 0.093
  45. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med. 1992 Jul 16; 327(3):157-62.
    View in: PubMed
    Score: 0.085
  46. Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry. J Clin Endocrinol Metab. 2012 Jul; 97(7):E1342-7.
    View in: PubMed
    Score: 0.084
  47. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med. 1989 Mar 02; 320(9):559-65.
    View in: PubMed
    Score: 0.068
  48. Characterization of functionally typical and atypical types of polycystic ovary syndrome. J Clin Endocrinol Metab. 2009 May; 94(5):1587-94.
    View in: PubMed
    Score: 0.068
  49. Asymptomatic volunteers with a polycystic ovary are a functionally distinct but heterogeneous population. J Clin Endocrinol Metab. 2009 May; 94(5):1579-86.
    View in: PubMed
    Score: 0.068
  50. Identification of a functional polymorphism of the human type 5 17beta-hydroxysteroid dehydrogenase gene associated with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan; 91(1):270-6.
    View in: PubMed
    Score: 0.054
  51. Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab. 2003 Nov; 88(11):5137-44.
    View in: PubMed
    Score: 0.047
  52. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril. 2003 Apr; 79(4):932-7.
    View in: PubMed
    Score: 0.045
  53. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001 Apr; 86(4):1626-32.
    View in: PubMed
    Score: 0.039
  54. Diagnosis of the polycystic ovary syndrome in adolescence: comparison of adolescent and adult hyperandrogenism. J Pediatr Endocrinol Metab. 2000; 13 Suppl 5:1285-9.
    View in: PubMed
    Score: 0.036
  55. Molecular analysis of the gonadotropin-releasing hormone receptor in patients with polycystic ovary syndrome. Fertil Steril. 1999 Aug; 72(2):360-3.
    View in: PubMed
    Score: 0.035
  56. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci U S A. 1999 Jul 20; 96(15):8573-8.
    View in: PubMed
    Score: 0.035
  57. Gonadotropin-releasing hormone agonist as a probe for the pathogenesis and diagnosis of ovarian hyperandrogenism. Ann N Y Acad Sci. 1993 May 28; 687:162-81.
    View in: PubMed
    Score: 0.023
  58. Transmission ratio distortion at the INS-IGF2 VNTR. Nat Genet. 1999 Aug; 22(4):324-5.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.